A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer December 14, 2017 Type of Cancer Genito-Urinary Sponsor Seattle Genetics Protocol Number SGN22E-002 To Learn More Call 201-510-0910